Controlled release of bioactive PDGF-AA from a hydrogel/nanoparticle composite

Donaghue, Irja Elliott; Shoichet, Molly S.

doi:10.1016/j.actbio.2015.08.002

Cited by 33 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incorporation of synthetic or endogenously‐occurring molecules can direct desired biological responses to foreign materials, which has been demonstrated in the context of tissue engineered devices for islet transplantation . Tissue engineered devices have been loaded with factors designed to activate signaling networks involved in regenerative processes including vascular endothelial growth factor (VEGF), platelet‐derived growth factor (PDGF), transforming growth factor‐beta 1 (TGF‐β1), and sphingosine‐1‐phosphate . Sphingosine‐1‐phosphate (S1P) is a pleiotropic autocrine and paracrine signaling lipid that regulates the behavior of endothelial cells, smooth muscle cells, stem cells, and immune cells through its activity at five G‐protein‐coupled cell surface receptors (S1P1‐S1P5).…”

Section: Introductionmentioning

confidence: 99%

An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation

et al. 2017

View full text Add to dashboard Cite

Macroencapsulation is a powerful approach to increase the efficiency of extrahepatic pancreatic islet transplant. FTY720, a small molecule that activates signaling through sphingosine-1-phosphate receptors, is immunomodulatory and pro-angiogenic upon sustained delivery from biomaterials. While FTY720 (fingolimod, Gilenya) has been explored for organ transplantation, in the present work the effect of locally released FTY720 from novel nanofiber-based macroencapsulation membranes is explored for islet transplantation. We screened islet viability during culture with FTY720 and various biodegradable polymers. Islet viability is significantly reduced by the addition of high doses (≥500 ng/mL) of soluble FTY720. Among the polymers screened, islets have the highest viability when cultured with poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV). Therefore, PHBV was blended with polycaprolactone (PCL) for mechanical stability and electrospun into nanofibers. Islets had no detectable function ex vivo following 5 days or 12 h of subcutaneous implantation within our engineered device. Subsequently, we explored a preconditioning scheme in which islets are transplanted 2 weeks after FTY720-loaded nanofibers are implanted. This allows FTY720 to orchestrate a local regenerative milieu while preventing premature transplantation into avascular sites that contain high concentrations of FTY720. These results provide a foundation and motivation for further investigation into the use of FTY720 in preconditioning sites for efficacious islet transplantation.

show abstract

Section: Introductionmentioning

confidence: 99%

An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Co-inclusion of PEG in the NPs further slowed the PDGF-AA release and reduced the overall amount of PDGF-AA released, potentially due to increased aggregation. With PDGF-AA, more cells were labeled for Rip, suggesting higher oligodendrocyte populations (Elliott Donaghue and Shoichet, 2015). …”

Section: Biomaterials For Sci and Strategies To Tune The Rate Of Relementioning

confidence: 99%

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Ziemba

Gilbert

2017

Front. Pharmacol.

View full text Add to dashboard Cite

Affecting approximately 17,000 new people each year, spinal cord injury (SCI) is a devastating injury that leads to permanent paraplegia or tetraplegia. Current pharmacological approaches are limited in their ability to ameliorate this injury pathophysiology, as many are not delivered locally, for a sustained duration, or at the correct injury time point. With this review, we aim to communicate the importance of combinatorial biomaterial and pharmacological approaches that target certain aspects of the dynamically changing pathophysiology of SCI. After reviewing the pathophysiology timeline, we present experimental biomaterial approaches to provide local sustained doses of drug. In this review, we present studies using a variety of biomaterials, including hydrogels, particles, and fibers/conduits for drug delivery. Subsequently, we discuss how each may be manipulated to optimize drug release during a specific time frame following SCI. Developing polymer biomaterials that can effectively release drug to target specific aspects of SCI pathophysiology will result in more efficacious approaches leading to better regeneration and recovery following SCI.

show abstract

“…For example, platelet‐derived growth factor‐BB (PDGF‐BB) has previously been encapsulated and released from polymeric nanoparticles. PDGF‐AA was encapsulated, with high efficiency, in poly(lactide‐co‐glycolide) nanoparticles, and its release from the drug delivery system was followed over 21 days . Magnetic gelatin nanospheres loaded with VEGF plasmid (5–20 nm) were intra‐arterially injected and used in a rabbit hind limb ischemia model, resulting in 50% increase in blood vessel density compared to empty nanospheres.…”

Section: The Strategies To Improve the Delivery Of Growth Factorsmentioning

confidence: 99%

Delivery of growth factor‐based therapeutics in vascular diseases: Challenges and strategies

et al. 2017

Biotechnology Journal

View full text Add to dashboard Cite

Either cardiovascular or peripheral vascular diseases have become the major cause of morbidity and mortality worldwide. Recently, growth factors therapeutics, whatever administrated in form of exogenous growth factors or their relevant genes have been discovered to be an effective strategy for the prevention and therapy of vascular diseases, because of their promoting angiogenesis. Besides, as an alternative, stem cell-based therapy has been also developed in view of their paracrine-mediated effect or ability of differentiation toward angiogenesis-related cells under assistance of growth factors. Despite of being specific and potent, no matter growth factors or stem cells-based therapy, their full clinical transformation is limited from bench to bedside. In this review, the potential choices of therapeutic modes based on types of different growth factors or stem cells were firstly summarized for vascular diseases. The confronted various challenges such as lack of non-invasive delivery method, the physiochemical challenge, the short half-life time, and poor cell survival, were carefully analyzed for these therapeutic modes. Various strategies to overcome these limitations are put forward from the perspective of drug delivery. The expertised design of a suitable delivery form will undoubtedly provide valuable insight into their clinical application in the regenerative medicine.

show abstract

Controlled release of bioactive PDGF-AA from a hydrogel/nanoparticle composite

Cited by 33 publications

References 34 publications

An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation

An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation

Biomaterials for Local, Controlled Drug Delivery to the Injured Spinal Cord

Delivery of growth factor‐based therapeutics in vascular diseases: Challenges and strategies

Contact Info

Product

Resources

About